GRAIL Posts 26% Revenue Growth on Galleri Test Expansion
Event summary
- GRAIL sold over 185,000 Galleri tests in 2025, growing U.S. revenue 26% YoY to $136.8M
- Completed FDA PMA submission for Galleri in January 2026
- NHS-Galleri trial showed 4x higher cancer detection rate vs. standard care
- PATHFINDER 2 study analysis completed with 35,000 participants
- Cash position of $904.4M provides runway into 2030
The big picture
GRAIL's strong 2025 performance reflects growing acceptance of multi-cancer early detection tests, particularly as healthcare systems seek cost-effective ways to improve cancer outcomes. The company's strategic focus on regulatory approval and digital health partnerships positions it at the forefront of a market projected to reach $10B by 2030. Success will depend on maintaining clinical differentiation while navigating complex reimbursement landscapes.
What we're watching
- Regulatory Timing
- Whether FDA approval will materialize in 2026 and its potential impact on commercial adoption
- Reimbursement Dynamics
- How Medicare coverage expansion will affect test accessibility and revenue growth
- Competitive Positioning
- The pace at which GRAIL can solidify market leadership before competitors scale similar offerings
Related topics